EUVIMEDEUVIMED entdecken
Crossref

Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody–induced skin toxicities in real-world metastatic colorectal cancer treatment

Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara

Supportive Care in Cancer · 2023

DOI: 10.1007/s00520-023-07973-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2023. Verfasst von Yoshitaka Saito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-jo 15-chome, Te…. Hauptthemen laut MEDLINE: Paronychia, Colorectal Neoplasms, Antineoplastic Agents, Exanthema. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies are effective in treating RAS wild-type metastatic colorectal cancer (mCRC). However, their administration induces skin toxicity, markedly reducing patients' quality of life. This study is aimed at identifying the risk factors associated with anti-EGFR monoclonal antibody-induced skin toxicities. METHODS: Patients with mCRC (n = 116) who received anti-EGFR monoclonal antibody treatment were retrospectively evaluated. Primary endpoint was evaluation of the risk factors for grade ≥ 2 overall skin toxicities during all the treatment periods. Furthermore, factors associated with each grade ≥ 2 skin symptoms were assessed. RESULTS: Incidence of total grade ≥ 2 skin toxicity symptoms was 61.2%, and those of grade ≥ 2 rash, dry skin, fissures, and paronychia were 34.5%, 25.9%, 20.7%, and 25.0%, respectively. Multivariate logistic regression analyses revealed that liver metastasis was an independent risk factor for overall grade ≥ 2 skin toxicities (adjusted odds ratio [OR], 2.88; 95% confidence interval [CI], 1.22-6.78; P = 0.02) and prophylactic administration of antibiotics as a preventive factor (OR 0.10; 95%CI 0.01-0.91; P = 0.04). For grade ≥ 2 rash, prophylactic use of systemic antibiotics and topical steroid ointment was a preventive factor (OR 0.37; 95%CI 0.16-0.89; P = 0.03). Moreover, liver metastasis (OR 8.37; 95%CI 1.98-35.47; P = 0.004) and prophylactic administration of antibiotics (OR 0.15; 95%CI 0.03-0.76; P = 0.02) were significantly associated with grade ≥ 2 paronychia. CONCLUSION: Liver metastasis was suggested to be a risk factor for the incidence of overall grade ≥ 2 skin toxicities; moreover, preemptive systemic antibiotic administration drastically decreased this risk during all periods of anti-EGFR treatment for mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParonychiaColorectal NeoplasmsAntineoplastic AgentsExanthemaColonic NeoplasmsRectal NeoplasmsHumansPanitumumabCetuximabQuality of LifeRetrospective StudiesErbB ReceptorsAntibodies, MonoclonalAnti-Bacterial AgentsRisk Factors

Stichwörter der Autor:innen

Anti-epidermal growth factor receptor monoclonal antibodyCetuximabPanitumumabRashRisk factorSkin toxicity

Substanzen

PanitumumabCetuximabErbB ReceptorsAntibodies, MonoclonalAntineoplastic AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-jo 15-chome, Teine-ku, Sapporo, 006-8585, Japan. saito-yo@hus.ac.jp.
  • Department of Pharmacy, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan. saito-yo@hus.ac.jp.
  • Department of Pharmacy, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.
  • Cancer Center, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.
  • Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo, 060-0812, Japan.

Zitieren

APA

Saito, Y., Uchiyama, K., Takekuma, Y., Komatsu, Y., & Sugawara, M. (2023). Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody–induced skin toxicities in real-world metastatic colorectal cancer treatment. Supportive Care in Cancer. https://doi.org/10.1007/s00520-023-07973-3

Vancouver

Saito Y, Uchiyama K, Takekuma Y, Komatsu Y, Sugawara M. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody–induced skin toxicities in real-world metastatic colorectal cancer treatment. Supportive Care in Cancer. 2023. doi:10.1007/s00520-023-07973-3

BibTeX
@article{Saito2023,
  author = {Saito, Yoshitaka and Uchiyama, Kazuki and Takekuma, Yoh and Komatsu, Yoshito and Sugawara, Mitsuru},
  title = {Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody–induced skin toxicities in real-world metastatic colorectal cancer treatment},
  journal = {Supportive Care in Cancer},
  year = {2023},
  doi = {10.1007/s00520-023-07973-3}
}
Kostenlos starten →